ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT06580717
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT06580717
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06580717. Randomized; single masking; primary purpose treatment. Start 2024-10-15 (actual); primary completion 2026-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
- Condition
- Nonobstructive Hypertrophic Cardiomyopathy
- Intervention (Drug)
- enavogliflozin 0.3mg
- Intervention (Drug)
- enavogliflozin Placebo
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct06580717- Content hash
558d82032961b4dd4d4f8ed3485fb7d20d31e4ff894b90c8f39f02aadd134416